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Due to small numbers of reported patients with pathogenic variants in single genes, the pheno-
typic spectrum associated with genes causing neurodevelopmental disorders such as intellec-
tual disability (ID) and autism spectrum disorder is expanding. Among these genes is KLF7
(Krüppel-like factor 7), which is located at 2q33.3 and has been implicated in several develop-
mental processes. KLF7 has been proposed to be a candidate gene for the phenotype of autism
features seen in patients with a 2q33.3q34 deletion. Herein, we report 4 unrelated individuals
with de novo KLF7 missense variants who share similar clinical features of developmental
delay/ID, hypotonia, feeding/swallowing issues, psychiatric features and neuromuscular symp-
toms, and add to the knowledge about the phenotypic spectrum associated with KLF7
haploinsufficiency.
KEYWORDS
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1 | INTRODUCTION
De novo genetic/genomic variants are increasingly acknowledged as a
significant etiology of neurodevelopmental disorders such as intellec-
tual disability (ID) and autism spectrum disorder (ASD).1–3 For geneti-
cally heterogeneous disorders such as developmental delay (DD) and
ID, diagnostic-exome sequencing (DES) can identify a genetic etiology
in up to 30% of cases when traditional genetic testing is inconclusive.4
During the past decade, substantial advancements have been made in
elucidating the genetic causes of neurodevelopmental disorders. How-
ever, over half of individuals with neurodevelopmental disorders still
do not have an identified genetic etiology.5,6
KLF7 (Krüppel-like factor 7, OMIM 604865), encodes a tran-
scription factor belonging to the KLF family characterized by the
presence of zinc coordinating (Zn) di-cysteine: di-histidine motif
(C2H2) and sequence homology to the Drosophila segmentation
gene product Krüppel.7 KLF7 has been implicated in several
developmental processes and may be involved in the regulation of
postmitotic differentiation of progenitor cells, neuronal morpho-
genesis, and/or phenotype maintenance.8 Emerging evidence sug-
gests that KLF7 haploinsufficiency results in a recognizable
neurodevelopmental phenotype. Located at 2q33.3, KLF7 has
been proposed to be one of the possible candidate genes for the
phenotype associated to the 2q33.3q34 deletion which has been
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reported in patients with ASD.9–12 Additionally, these patients
present with microcephaly, hypotonia, psychomotor retardation
and mild dysmorphic features.
Herein, we report 4 unrelated affected individuals with de novo
missense variants in KLF7 detected by DES with of DD/ID, neuro-
muscular and psychiatric complications.
1.1 | Clinical report
Clinical characteristics of the 4 patients are summarized in Table 1.
1.1.1 | Patient 1
Patient 1 was born at 38 weeks, 6 pounds 10 oz by c-section due to
breech position to Ashkenazi Jewish, non-consanguineous parents.
The pregnancy was uncomplicated with possible decreased fetal
movements. He had jaundice requiring phototherapy due to difficulty
feeding and also had torticollis. The patient was seen by neurology
and began occupational and physical therapy at 6 months of age due
to diffuse muscle weakness. He rolled over at 6 months of age, sat
unassisted at 11 months and began crawling and pulling to stand at
15 months with the aid of therapies. Vision and hearing evaluations
at 8 months was normal. At approximately 1 year, he had mildly ele-
vated creatine kinase levels (353 and 419 units per liter). He was
evaluated in genetics clinic at 15 months for possible myopathy due
to gross motor delay, proximal muscle weakness and positive Gower’s
sign. At 21 months, he wore ankle braces for support in ambulation,
had mild torticollis, pes planus, positive Gower’s sign, and mildly
wide-based gait. He did not cooperate with formal strength testing at
that time. Language was reported to be mildly delayed and there
were reports of some difficulty in swallowing. Muscle weakness later
resolved; however, he remained hypotonic with language and cogni-
tive delays. Developmental testing at 3 years 7 months showed a lan-
guage developmental quotient (DQ) of 71% and cognitive DQ of
73%. He was also diagnosed with ASD and anxiety. The patient was
non-dysmorphic with normal growth parameters. Brain MRIs at
20 months and 4 years showed stable mild ventriculomegaly. On
follow-up evaluation at age 4 years, his muscle tone continued to be
low and his running was slow, but he no longer used a Gower’s
maneuver and strength was normal in upper and lower extremities.
Family history was non-contributory. Prior normal genetic testing
included NEB deletion testing for the p.R2478_D2512 deletion com-
mon in the Ashkenazi Jewish population and SMN1 copy number
testing due to hypotonia.
1.1.2 | Patient 2
Patient 2 was initially seen at birth and is currently 16 years old. She
was born at 35 weeks at 2 pounds, 12 oz, 36.5 cm, head circumfer-
ence 29.5 cm (<10th% for gestational age) to Irish, German
non-consanguineous parents. Pregnancy and birth history were com-
plicated only by decreased fetal movements. After birth inability to
regulate body temperature, hypotonia and feeding difficulties associ-
ated with gastroesophageal reflux disease were noted. At 3 weeks of
age she developed episodes of apnea that prompted monitoring and
recurring hospital admissions. She is reported to be non-verbal, have
ID, lower hypertonia, contractures, mild positional scoliosis, cerebral
palsy, strabismus requiring surgery and is described as anxious and
shy. Additional features included failure to thrive, short stature,
microcephaly, no tear production, little-to-absent sweating and mild
dysmorphic features (Figure 1). Family history was non-contributory.
Prior normal testing included normal karyotype, chromosomal micro-
array, congenital disorder of glycosylation testing, methylation for
Angelman syndrome and a metabolic work-up.
1.1.3 | Patient 3
Patient 3 had been seen by a pediatric neurologist at regular intervals
since age 4.5 years. At 15 years old she is reported to have ID (IQ 64),
attention deficit disorder/anxiety, neonatal feeding difficulties, motor
dyspraxia, upper extremities hypotonia and lower extremity hyperto-
nia. She was reported as “large for her age.” Family history was non-
contributory. Prior normal testing included normal metabolic screening
including a skin biopsy for peroxysisomal function, single nucleotide
polymorphism (SNP) array, molecular tests for Sotos and Fragile X syn-
dromes, electromyography (EMG) and electroencephalography (EEG).
1.1.4 | Patient 4
Patient 4 is a 2 years and 4 months old male with global DD and
hypotonia. ID has not been assessed formally, but he spoke his first
words at 2 years of age and walked independently at 26 months. He
also has hypertelorism. Family history was non-contributory. Prior
normal testing included normal metabolic testing and SNP array.
2 | METHODS
2.1 | Exome sequencing
For all patients, trio whole-exome sequencing was performed with
proband and both biological parents on genomic DNA isolated from
blood. Diagnostically relevant variants were confirmed by Sanger
sequencing. For patient 1, DES was performed by Ambry Genetics
Laboratory. Samples were prepared using the SeqCapEZ VCR 2.0
(Roche NimbleGen, Madison, Wisconsin) and sequenced on the Illu-
mina HiSeq 2000 Sequencer (Illumina, San Diego, California). Data
annotation and interpretation were performed as previously
reported.4 For patient 2, DES was performed at GeneDx Laboratory
with methods as previously reported.13
For patients 3 and 4 exome sequencing and variant calling, a
parent-offspring trio approach was used as described previously.3
Briefly, the exome was captured using the Agilent SureSelect v4 kit
(Agilent, Santa Clara, California). Exome libraries were sequenced on an
Illumina HiSeq2000 instrument (Illumina) with 101 bp paired-end reads
at a median coverage of ×75. Sequence reads were aligned to the
hg19 reference genome using BWA version 0.5.9-r16.14 Variants were
subsequently called by the GATK unified genotyper, version 3.2-2 and
annotated using a custom diagnostic annotation pipeline.15 All variants
were classified utilizing ACMG standards and guidelines.16
Informed consent was obtained from all patients and family
members undergoing sequencing. All research described in this case
report was conducted in accordance with the World Medical Associa-
tion Declaration of Helsinki. The clinical information presented herein
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was collected during the routine clinical care of a patient and this
study is exempt from Institutional Research Board approval. All sub-
jects participating in this study provided signed, written consent
allowing for the publication of their clinical photographs and/or data.
In the case of minors, signed written consent was provided by their
parents or legal guardians.
Individuals were identified through GeneMatcher.17
2.2 | Structural analysis
The structure of KLF7 with bound DNA was modeled based on the
crystal structure of KLF4 bound to DNA (PDB: 4M9E).18 The Zinc fin-
ger domains of KLF4 and KLF7 share 73% identity, with 100% con-
servation observed at DNA interacting residues. The program Coot19
was used to change the amino acids that differed between the
sequences of KLF4 and KLF7, most of which were solvent-exposed,
and reasonable sidechain rotamers were chosen manually. In silico
mutagenesis of Asp 264 to Asn was carried out using FoldX.20 Model
graphics were generated using Pymol (The PyMOL Molecular
Graphics System, Version 1.7.1 Schrödinger, LLC.). Motifs were iden-
tified using the web server ELM.21 Disorder was predicted by
IUPRED and GlobPlot.22 Low sequence complexity was predicted by
SMART.23,24
3 | RESULTS
We report patients from 4 unrelated families with a similar pheno-
type found to have probably gene damaging de novo variants in
KLF7. The genotypes and analysis of the variants are presented in
Figure 1. All sequence variants are described in reference to RefSeq
transcript NM_003709. In patients 1 and 4, DES independently iden-
tified the heterozygous de novo missense variant KLF7 c.410C>T
(p.T137M). In patients 2 and 3, DES identified the heterozygous de
novo missense variants KLF7 c.790G>A (p.D264N) and c.415C>T
(p.P139S), respectively.
3.1 | Structural interpretation of the variants
The KLF7 c.410C>T (p.T137M) and c.415C>T (p.P139S) variants lie in
a flexible, unstructured sequence, in the N-terminal regulatory region
of KLF7, whereas the c.790G>A (p.D264N) variant is located in the
C-terminal zinc finger-containing DNA-binding domain (Figure 2A).
The 3 KLF7 variants are all in highly conserved amino acid positions
and are not present in the ExAC database.25 The 2 N-terminal vari-
ants are contained in a span containing 2 noteworthy linear motifs—
“Skp1--Cullin--Fbox-WD40 (SCF) ubiquitin ligase target” motif and a
“glycogen synthase kinase (GSK) target” motif (Figure 2B). The “GSK
target” motif—defined by 2 serine (S) or threonine (T) residues spaced
4 residues apart ([S/T]-X-X-X-[S/T])—identifies the protein to be
phosphorylated by GSK. Within this GSK motif is the “SCF ubiquitin
ligase target” motif, defined as the GSK motif where the positions
immediately after each S/T are proline ([S/T]-P-X-X-[S/T]-P). Upon
phosphorylation at both S/T positions by the kinase, this site would
be recognized by the SCF ubiquitination complex, which promotes
degradation. In the paralog KLF2, which has the same motif, direct
variant of these motifs negatively impacted its SCF-mediated degra-
dation in vitro and in vivo indicating a key biological role for this
sequence.26 In KLF7, the variant c.410C>T (p.T137M) sits within the
motifs and is anticipated to disrupt this motif by eliminating a phos-
phorylation site; on the other hand there is no evidence that,
FIGURE 1 Patient 2 at (A) 3 years,
(B) 8 years, (C) 10 years, (D) 12 years,
and (E) 17 years
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c.415C>T (p.P139S) would impact the motif and probably mechanism
of disruption of this variant cannot be elucidated from available infor-
mation, suggesting that this region warrants deeper functional inves-
tigation. The third variant, c.790G>A (p.D264N), is located in the
C-terminal zinc finger-containing DNA-binding domain, shown to
bind to the minimal enhancer of the TrkA gene, which encodes the
high affinity receptor for nerve growth factor. This variant involves
one of the specificity residues of the zinc-finger domain involved in
q33 
SCF 
Zn1 Zn2 Zn3 
Chr2 
KLF7 
Patients 1 & 4 Patient 2 Patient 3 
RefSeq ID NM_003709 NM_003709 NM_003709 
Nucleotide change c.410C>T c.790G>A c.415C>T
Amino acid change p.D264Np.T137M p.P139S
Protein domain GSK/SCF motif zinc finger GSK/SCF motif 
PolyPhen2 
1.00 (Probably 
Damaging) 
1.00 (Probably 
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SIFT 
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Damaging) 
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MutationTaster Disease Causing Disease Causing Disease Causing 
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FIGURE 2 (A) KLF7 Gene Structure-Ideogram of the KLF7 centered by the gene structure and the protein architecture on the bottom. The
arrow line demarks the prediction (shown as a squiggle line) of the proteins tendency to be disordered (squiggle above the line) or structured
(squiggle below the line). The zinc-finger (C2H2 type) domains are label Zn1, Zn2, and Zn3, respectively. The Skp1--Cullin--Fbox-WD40 (SCF) is
also indicated. Observed variants are indicated by red triangles. (B) KLF7 Structural Motif. GSK, glycogen synthase kinase. (C) conservation of
variants, and (D) in silico predictions
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interactions with DNA. An variant of this residue is probably to shift
DNA binding selectivity due to altered interaction possibilities, which
may result in impaired activation of target genes which has been
observed in the zinc-finger proteins (Figure 3).
4 | DISCUSSION
We report patients from 4 unrelated families with a similar phenotype
found to have probably gene damaging de novo variants in KLF7.
Among the 3 different de novo missense variants identified in our
cohort, there is one heterozygote with the p.T137M in GnomAD, and
one heterozygote with p.P139L (a different substitution at same resi-
due) in GnomAD.25 An additional female patient with ID was reported
through ClinVar, carrying the same de novo variant as our patient 2 -
(ClinVar submission accession number SCV000493088.1). The variant
was reported as of uncertain clinical significance; no other details were
available. While the individuals reported in GnomAD are not expected
to have early-onset severe disorder, due to the variability present in
patients 1 and 4, it is possible that this individual might be mildly
affected. Without further analysis of this variant in additional individ-
uals, a potential a female protective model cannot be ruled out.27
4.1 | Phenotype of patients with KLF7 variants and
2q33.3q34deletion
DD/ID, hypotonia, feeding/swallowing issues, psychiatric features
and neuromuscular symptoms were present in 3 patients in our
cohort, with the additional patient showing mild neuromuscular
symptoms, DD, but being too young for formal psychiatric testing.
The additional individual present in ClinVar was reported with at
least ID. These characteristics are similar to the individuals reported
with the 2q33.3q34deletion syndrome, although the phenotype is
also highly variable (reviewed in Table 1).9–12 Of the 4 previously
reported patients in the literatures with the deletion, varying
degrees of DD/ID, hyptonia, feeding/swallowing issues, psychiatric
features and neuromuscular issues were reported along with dys-
morphic features, seizures and microcephaly. None of the cases in
our cohort had seizures. Dysmorphic features were reported in
3 individuals with the overlapping deletion and in one affected indi-
vidual of our cohort. Growth retardation and microcephaly were
reported in 2 individuals with the 2q deletion and one individual in
our cohort. In contrast, one individual in our cohort was reported
with tall stature and macrocephaly. Ronzoni et al28 also reported an
additional patient with a KLF7 deletion. This deletion also included
more than 50 RefSeq genes; 17 listed as human disease genes in
OMIM. Therefore, it is difficult to establish correlation to individuals
with KLF7 only variants especially due to the cumulative nature of
these genes, but suggests that KLF7 does have a role in neurodeve-
lopmental features.
The variability between the 2 patients within our cohort with
the same variant may either be explained by the lack of phenotype/
genotype connection within KLF7 or the young age of the patient.
Further chronological study of the patients within this cohort and
the discovery of additional patients may be helpful in elucidating
this construct.
(A) (B)
FIGURE 3 The interactions of KLF7 with target DNA sequence. (A) Schematic representation of interactions between the Zinc fingers of KLF7
and DNA, with region of interest emphasized. Each position shows possible recognized bases as determined experimentally for KLF4. Bases
present in crystal structure bolded. Bases defined specifically by interactions shown in red. Hydrogen-bonding and electrostatic interaction in
region of interest shown with red arrows. (B) Structural representation of interactions involving D264, and predicted interactions involving
N264. Hydrogen bonds and electrostatic interactions shown with dashed yellow lines. D264 is one of the specificity residues of the Zinc-finger
involved in interactions with DNA. An variant of this residue is probably to shift DNA-binding selectivity due to altered interaction possibilities,
which may result in impaired activation of target genes
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4.2 | Pathogenic mechanisms of KLF7 variants
Homozygous Klf7 null (Klf7−/−) mice were born at expected Mende-
lian frequencies but a majority of them (98.5%) died within the first
3 days of life with very little or no milk in their stomachs, hypopnea
and cyanosis.29 Additionally, these mice showed defects in neurite
outgrowth, axonal misprojection at specific locations within the ner-
vous system including the olfactory and visual systems, cerebral cor-
tex and hippocampus and reduced dendritic branching in the
hippocampus.29 Abnormal corpus callosum (CC) in the null mouse
was seen due to failure of the fibers of CC to cross the midline, a
missing or severely disrupted anterior commissure and a reduction in
the size of the fimbria.29,30 Lei et al30 reported that sensory nocicep-
tive neurons in Klf7−/− newborn mice are significantly reduced due to
increased apoptosis. The authors find that TrkA expression is reduced
in the DRG neurons of Klf7−/− mice because Klf7 has been shown to
bind to a minimal enhancer in the TrkA upstream promoter region.
Using an RNAi-mediated knockdown approach in the neuroe-
pithelial cell line PC12, Caiazzo et al31 observed that downregulation
of KLF7 gene expression caused silencing of genes crucial for neuro-
nal differentiation, namely MAP2 and the high affinity receptor for
NGF, TrkA. Downregulation of TrkA caused a failure of shKlf7-PC12
stable clones to differentiate into neurons. KLF7 role in cellular differ-
entiation was not limited to the nervous system. Klf7-silenced embry-
onic stem cells fail to differentiate into cardiomyocytes, and Klf7−/−
mouse embryonic fibroblasts display impaired adipogenesis and
enhanced osteogenesis ability.
The roles of proteins in the KLF family have been reviewed
extensively and although a few of them have nervous system specific
roles, none of them have been implicated in human disease to date.32
However, mutations affecting KLF7-interacting proteins have been
shown to cause genetic diseases in humans. For example, a dominant
mutation in the FBXO38 gene, encoding the F-box protein 38, has
been reported in members of 2 unrelated families affected by a dis-
tinct form of distal spinal muscular atrophy which initially manifests
as calf weakness.33 FBXO38 is a transcriptional coactivator of KLF7
and the authors report that this mutation led to dysregulation of
KLF7 target genes and impairment of neurite outgrowth in primary
motor neurons indicating a critical role for FBXO38 and KLF7 in axo-
nal development and neuronal maintenance. One of the KLF7 target
genes is L1CAM, encoding the neural cell adhesion molecule L1 that
plays essential roles in neuronal migration, axon growth and guidance
and synaptic plasticity in both the central and peripheral nervous sys-
tems34 X-linked recessive mutations in the L1CAM gene have been
shown to cause hydrocephalus, a phenotype associated with enlarged
cerebral ventricles, mental retardation and often with spastic parapar-
esis and adducted thumbs (OMIM: 307000).
5 | CONCLUSION
In summary, we present the clinical phenotype information of
4 patients with de novo KLF7 variants, supporting the relationship of
the gene with neurodevelopmental features. We hypothesize that
the core phenotype of DD/ID, neuromuscular and psychiatric symp-
toms is present in individuals with KLF7 variants along with potential
additional features. We report the varying phenotype of the individ-
uals with these variants. It is anticipated that additional individuals
with KLF7 variants will be identified, adding to the knowledge of the
clinical spectrum and pathogenicity. Additional studies on patients
with KLF7 variants and functional studies of these variants are neces-
sary to further elucidate the correlation between genotype and phe-
notype, preferably supported by further investigations of the
molecular mechanism of KLF7 during neurological development and
function.
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